Therapeutic area intelligence for Antipsychotic with 29 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 29
Catalysts: 0
Companies: 10

Companies

Actavis Labs →

Alembic Pharmaceuticals →

Amneal Pharmaceuticals →

Aurobindo Pharma →

Heritage Pharma →

InvaGen Pharmaceuticals →

Novitium Pharma →

Saptalis Pharmaceuticals →

Torrent Pharmaceuticals →

Zydus Pharmaceuticals →

Assets

Recent signals(29)

RegulatoryAugust 6, 2026

FDA Acceptance of Zyprexa Relprevv Supplement by Cheplapharm

The FDA has accepted a supplemental application for Zyprexa Relprevv (Olanzapine Pamoate) from Cheplapharm.

RegulatoryAugust 6, 2026

FDA Approval Process Update for Paliperidone (ANDA205402)

The FDA has received an application for Paliperidone under ANDA205402, currently in the approval process.

RegulatoryAugust 5, 2026

FDA Approves Supplement for Risperidone by Heritage Pharma

The FDA has approved a supplement for the ANDA076228 application for Risperidone submitted by Heritage Pharma.

RegulatoryAugust 3, 2026

FDA Approval Process Update for Perphenazine by Zydus Pharmaceuticals

The FDA has an active application (ANDA205232) for Perphenazine submitted by Zydus Pharmaceuticals, currently under review.

RegulatoryJuly 29, 2026

FDA Approves Supplemental Application for Ziprasidone Hydrochloride

The FDA has approved a supplemental application for Ziprasidone Hydrochloride submitted by Chartwell RX.

StrategyJuly 28, 2026

FDA grants AP status for Quetiapine Fumarate ANDA206252 by Accord Healthcare

The FDA has granted approval status (AP) for the ANDA206252 application for Quetiapine Fumarate submitted by Accord Healthcare.

RegulatoryJuly 26, 2026

FDA grants AP status for Saptalis' Sonazine (Chlorpromazine Hydrochloride)

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Sonazine, a chlorpromazine hydrochloride product from Saptalis Pharmaceuticals.

StrategyJuly 26, 2026

FDA Grants AP Status for Lurasidone Hydrochloride ANDA208055

The FDA has granted approval status (AP) for the ANDA208055 application for Lurasidone Hydrochloride submitted by Torrent.

StrategyJuly 26, 2026

FDA Approves Pimozide Application ANDA219897 from Novitium Pharma

The FDA has approved the application ANDA219897 for Pimozide submitted by Novitium Pharma.

StrategyJuly 22, 2026

FDA Grants Approval for Lurasidone Hydrochloride ANDA208047 by Dr. Reddy's

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Lurasidone Hydrochloride submitted by Dr.

RegulatoryJuly 20, 2026

Aurobindo Pharma's Olanzapine ANDA203708 Receives AP Status from FDA

Aurobindo Pharma's application for olanzapine has received Abbreviated Approval (AP) status from the FDA.

RegulatoryJuly 19, 2026

FDA Grants Supplement Approval for Lurasidone Hydrochloride by Amneal Pharmaceuticals

The FDA has granted approval for a supplemental application for Lurasidone Hydrochloride submitted by Amneal Pharmaceuticals.

RegulatoryJuly 19, 2026

Aurobindo Pharma's Lurasidone Hydrochloride ANDA208045 Receives AP Status

Aurobindo Pharma's ANDA for Lurasidone Hydrochloride has received Abbreviated Approval (AP) status from the FDA.

StrategyJuly 19, 2026

FDA Grants Approval for Lurasidone Hydrochloride ANDA208028

The FDA has granted approval for ANDA208028, a generic version of Lurasidone Hydrochloride, submitted by InvaGen Pharmaceuticals.

RegulatoryJuly 16, 2026

FDA Acceptance of Supplemental Application for Lurasidone Hydrochloride by Zydus Pharms

The FDA has accepted the supplemental application ANDA208052 for Lurasidone Hydrochloride submitted by Zydus Pharms.

RegulatoryJuly 14, 2026

FDA Accepts Supplemental Application for Zyprexa Relprevv by Cheplapharm

The FDA has accepted a supplemental application for Zyprexa Relprevv, an antipsychotic medication.

StrategyJuly 14, 2026

FDA Grants Approval for Paliperidone ANDA205402 by I3 PHARMS

The FDA has granted approval for ANDA205402, a generic formulation of paliperidone, submitted by I3 PHARMS.

StrategyJuly 13, 2026

FDA Approval Update for Risperidone by Heritage Pharma

Heritage Pharma has received an Abbreviated New Drug Application (ANDA) approval for Risperidone.

RegulatoryJuly 11, 2026

FDA Grants AP Status for Zydus' Perphenazine Supplement

The FDA has granted an Abbreviated New Drug Application (ANDA) AP status for Zydus Pharmaceuticals' supplement for Perphenazine.

RegulatoryJuly 11, 2026

FDA Accepts Supplement for REXULTI (Brexpiprazole) Submission

The FDA has accepted a supplemental application for REXULTI (brexpiprazole) from Otsuka.

RegulatoryJuly 11, 2026

FDA Approves Supplemental Application for PERSERIS Kit by INDIVIOR

The FDA has approved a supplemental application for the PERSERIS Kit, which contains risperidone.

RegulatoryJuly 9, 2026

FDA Accepts Supplement for Risperidone by Actavis Labs

The FDA has accepted a supplemental application for Risperidone submitted by Actavis Labs.

RegulatoryJuly 6, 2026

FDA Accepts Supplement for Ziprasidone Hydrochloride by Chartwell RX

The FDA has accepted a supplemental application for Ziprasidone Hydrochloride submitted by Chartwell RX.

RegulatoryJuly 3, 2026

FDA Accepts Supplement for Sonazine (Chlorpromazine Hydrochloride)

The FDA has accepted a supplemental application for Sonazine, a formulation of Chlorpromazine Hydrochloride, by Saptalis Pharmaceuticals.

RegulatoryJuly 1, 2026

FDA Grants AP Status for Haloperidol Decanoate ANDA214507

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Haloperidol Decanoate submitted by Meitheal.

StrategyJune 30, 2026

FDA Grants Approval for Haloperidol ANDA214470 by Alembic

The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 214470 for Haloperidol submitted by Alembic.

StrategyJune 21, 2026

FDA Grants AP Status for Risperidone ANDA077494 Submission

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Risperidone under application number ANDA077494.

CompetitiveJune 10, 2026

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

Torrent's ANDA for Lurasidone Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

StrategyJune 9, 2026

FDA Grants Approval for Pimozide ANDA219897 by Novitium Pharma

The FDA has granted approval for ANDA219897, a generic formulation of Pimozide submitted by Novitium Pharma.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.